brigham buhler bpc 157 FDA panel narrowly backs unapproved peptide drug touted by Joe Rogan and other influencers Our founder, Brigham Buhler, was

They must be reconstituted with a sterile solvent before use

Use our brand shop or convenient product search to quickly find the medicine or healthcare product you need

Its compounding-pathway status is unsettled: ibutamoren mesylate was nominated for inclusion on FDA's Section 503A bulk drug substances list, and the Pharmacy Compounding Advisory Committee reviewed the nomination at its October 29, 2024 meeting and voted against recommending it for the list, citing concerns about the strength of the safety and efficacy evidence

BPC-157 is not FDA-approved to treat, cure, or prevent any disease

2020 Jan 30;25(3):609

doi: 10.3390/molecules28020619